Patients who had on-treatment AE-IPF also had significantly higher plasma levels of KL-6 (3.11 ng/mL [IQR 1.38–5.07] versus 1.03 ng/mL [IQR 0.48–1.86]; p = 0.001) and SPA (412.6 pg/mL [IQR 181.8–478.5] versus 235.6 pg/mL [IQR 157.3–379.9]; p = 0.042) than those who did not have AE-IPF. Here, MUC1 is linked to idiopathic pulmonary fibrosis.